Electrophysiological mechanisms of sophocarpine as a potential antiarrhythmic agent

Acta Pharmacologica Sinica

Volumn 32, Issue 3, 2011, Pages 311-320

  Yang, Zhi Fang ^a   Li, Ci Zhen ^a   Wang, Wei ^a   Chen, Ying Min ^a   Zhang, Ying ^a   Liu, Yuan Mou ^a   Wang, Hong Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

action potential; anti arrhythmia; calcium current; potassium current; sodium current; sophocarpine; voltage clamp

Indexed keywords

AMIODARONE; CALCIUM ION; ISOPRENALINE; MATRINE; POTASSIUM ION; SODIUM ION;

ANIMAL CELL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GUINEA PIG; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART RATE VARIABILITY; HEART REPOLARIZATION; ISOLATED HEART; MALE; MICROELECTRODE; NEWBORN; NONHUMAN; POTASSIUM CURRENT; RABBIT; SINUS NODE MEMBRANE POTENTIAL; SODIUM CURRENT; TACHYCARDIA; VOLTAGE CLAMP;

ACTION POTENTIALS; ALKALOIDS; AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CELLS, CULTURED; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; GUINEA PIGS; HEART; MALE; MYOCYTES, CARDIAC; PAPILLARY MUSCLES; PATCH-CLAMP TECHNIQUES; RABBITS; SODIUM; TACHYCARDIA;

EID: 79952377034     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.207     Document Type: Article

References (35)

1. Zhang BH, Wang NS, Li XJ, Kong XJ, Cai YL. Anti-arrhythmic effects of matrine. Acta Pharmacol Sin 1990; 11: 253-7
2. Huang CY, Xie SR, Huang SY, Gao GY. Experimental studies of anti-arrhythmic effects of matrine. J Dalian Med Univ 2002; 24: 177-9.
3. Chen YM, Xu J, Li HB, Chen MF, Qian FR, Chen SX, et al. Effect of sophocarpine on ouabain-induced arrhythmia in guinea pigs. Chin J New Drugs Clin Rem 2008; 27: 576-8
4. 3 by sophocarpine. Chin J New Drugs Clin Rem 2006; 25: 709-12
5. Chen SX, Chen MF, Qian FR, Xie LS. A clinical research of sophocar-pine in treatment of viral myocarditis. Chin J Clin Cardiol 2005; 211: 608-11.
6. Chen YM, Xu J, Ye Q, Chen MF, Shen HF, Chen SX. Effect of sophocar-pine in raising ventricular fbrillation threshold and prolonging ventri-cular effective refractory period of early acute myocardial ischemia in canine. Chin J New Drugs Clin Rem 2006; 25: 252-5
7. Wang HW, Yang ZF, Zhang Y, Yang JM, Liu YM, Li CZ. Beta-receptor activa tion increases sodium current in guinea pig heart. Acta Pharmacol Sin 2009; 30: 1115-22.
8. Baetz D, Regula KM, Ens K, Shaw J, Kothari S, Yurkova N, et al. Nuclear factor kappaB-mediated cell survival involves transcriptiona silencing of the mitochondrial death gene BNIP3 in ventricular myo-cytes. Circulation 2005; 112: 3777-85 (Pubitemid 43739519)
9. Zhang Y, Zheng YQ, Wang HW, Yang Zf, Liu YM, Li CZ. Method for culturing neonatal rat cardiac myocytes and observation of its electro-physiological properties. J Shanghai Jiaotong Univ (Med Sci) 2007 27: 398-400
10. Yang ZF, Wang HW, Zheng YQ, Zhang Y, Liu YM, Li CZ. Possible arrhy-thmiogenic mechanism produced by ibuprofen1. Acta Pharmacol Sin 2008; 29: 421-9. (Pubitemid 351465504)
11. Liu YM, DeFelice LJ, Mazzanti M. Na channels that remain open throughout the cardiac action potential plateau. Biophys J 1992; 63 654-62
12. k in rabbit sinoatrial node myocytes: implications for SA node auto-maticity J Cardiovasc Pharmacol 1998; 32: 783-90 (Pubitemid 28506650)
13. Li CZ, Liu YM, Yang ZF, Wang HW, Yang JM. An improved method of isolation of rabbit sinus node cells and the perforated patch recording with amphotericin B. Chin J Appl Physiol 1999; 15: 89-92
14. + current in guinea-pig sino-atrial node cells. Br J Pharmacol 2002; 137: 253-62
15. Roukoz H, Saliba W. Dofetilide: a new class III anti-arrhythmic agent Expert Rev Cardiovasc Ther 2007; 5: 9-19. (Pubitemid 46157737)
16. + Channels. Yao Xue Xue Bao 2008; 43: 44-9
17. Katz AM. The Cardiac Action Potential. In: Kartz AM, editors. Physio-ogy of the heart 3rd ed. Philadelphia: Lippincott Williams & Wilkins 2001: P 478-516
18. Valenzuela C, Bennett PB. Voltage-and use-dependent modulation of calcium channel current in guinea pig ventricular cells by amiodarone and des-oxo-amiodarone. J Cardiovasc Pharmacol 1991; 17: 894-902
19. 2-adrenergic stimulation in the failing heart are due to enhanced SR Ca load. Circ Res 2008; 102: 1389-97
20. Tosaki A, Woodward B, Yamamoto F, Hearse DJ. Isoproterenol and the genesis of reperfusion-induced arrhythmias in isolated rat heart: adrenoceptor or free radical-mediated mechanisms? J Cardiovasc Pharmacol 1990; 15: 398-407 (Pubitemid 20063740)
21. Tosaki A, Braquet P. DMPO and reperfusion injury: Arrhythmia, heart function, electron spin resonance, and nuclear magnetic resonance studies in isolated working guinea pig hearts. Am Heart J 1990; 120: 819-30 (Pubitemid 20346146)
22. Tosaki A, Balint S, Szekeres L. Protective effect of lidocaine against schemia and reperfusion-induced arrhythmias and shifts of myo-cardial sodium, potassium, and calcium content. J Cardiovasc Pharmacol 1988; 12: 621-8
23. Katz AM. Arrhythmias II: Clinical Manifestations and Principles of Therapy In: Katz AM, editors. Physiology of the heart 3rd ed Philadelphia: Lippincott Williams & Wilkins 2001: P 580-629
24. Tosaki A, Balint S, Szekeres L. Pacing and reperfusion induced arrhythmias: protection by slow heart rate in the rat heart. Cardiovasc Res 1988; 22: 818-25 (Pubitemid 18268711)
25. + accumula-tion during myocardial ischemia. AM J Physiol 1986; 250: H982-91
26. Zuanetti G, DeFerrari GM, Priori SG, Schwartz PJ. Protective effect of vagal stimulation on reperfusion arrhythmias in cats. Circ Res 1987 61: 429-35 (Pubitemid 17145949)
27. Chen SX, Xu XH, Zhang DQ, Mei SW, Xie LS, Chen MF, et al. The study on the expression of IFN-γ and IL-10 in patients with viral myocarditis and their interference with Chinese drugs. Chin J Endocrinol Metab 2001; 21: 14-7
28. Zhao XJ, Guo DL, Wu Y, Liu TX, Yan GX. Effects of chronic amiodarone therapy on L-type calcium current recovery and action potentia duration of rabbit ventricular myocytes. Chin J Cardiol 2009; 37: 528-31
29. Singh BN. Expanding indications for the use of class III agents in patients at high risk for sudden death. J Cardiovasc Electr 1995; 6 887-900
30. Anderson JL. Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management. J Cardiovasc Electr 1995; 6: 880-6
31. Vassallo P, Trohman RG. Prescribing amiodarone an evidence-based review of clinical indications. J Am Med Assoc 2007; 298: 1312-22. (Pubitemid 47449439)
32. Sicouri S, Belardinelli L, Carlsson L, Antzelevitch C. Potent anti arrhy-thmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electr 2009; 20: 803-10
33. Kodama I, Kamiya K, Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999; 9: 20-8 (Pubitemid 29527987)
34. Singh BN. Amiodarone: A multifaceted antiarrhythmic drug. Curr Cardiol Rep 2006; 5: 349-55 (Pubitemid 44445922)
35. Li XL, Chu WM, Liu JL, Xue XR, Lu YJ, Shan HL, et al. Antiarrhythmic properties of long-term treatment with Matrine in arrhythmic rat nduced by coronary ligation. Biol Pharm Bull 2009; 32: 1521-6.